Evidence map›Paper›PMID 34340997›Full record

ArticleGut2022

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.

Gilaad G Kaplan, Christopher Ma, Carmen Charlton, Jamil N Kanji, Graham Tipples, Nastaran Sharifi, Michelle Herauf, Stephanie Coward, Richard J M Ingram, Lindsay Hracs and 2 more

Abstract readLetterComment
In one paragraph

Article in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Gilaad G Kaplan *Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada ggkaplan@ucalgary.ca.ORCID 0000-0003-2719-0556
Christopher Ma *Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-4698-9948
Carmen CharltonDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Jamil N KanjiAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
Graham TipplesAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
Nastaran SharifiDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Michelle HeraufDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Stephanie CowardDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Richard J M IngramDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Lindsay HracsDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Eric I BenchimolDepartment of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID 0000-0001-8855-3598
Remo PanaccioneDivision of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Inflammatory Bowel DiseasesAntibodies, ViralAntibody FormationCohort StudiesHumansSARS-CoV-2Antibodies, ViralCOVID-19IBD

Identifiers

PMID34340997
PMCPMC9120372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.